October is Breast Cancer Awareness Month and BriaCell (BCT) is advancing the fight with its immunotherapy.
Significant progress has been made in breast cancer support, prevention, detection, diagnosis, treatment, and care – yet the estimated 43,600 breast cancer deaths per year in the U.S. indicates a considerable need for more effective treatments.
BriaCell’s relentless drive to attack and destroy breast cancer tumours is supported through its clinical programs and partnerships with world-class cancer centers to recruit and treat patients.
Breast Cancer Awareness Month brings the awareness that BriaCell is not treating ‘subjects’ or ‘n=’. They're treating women – mothers, daughters, sisters, wives, and friends.
Breast cancer kills 120 women each day in the U.S. alone. BriaCell’s work has already demonstrated clinical benefit in trials thus far to patients who had failed multiple prior treatments.
BriaCell has emerged in 2021, with $57 million in cash as of July 31, 2021, and clinical advancements that support Briacell's mission. In June, it reported a 12.0 months overall survival benefit in advanced breast cancer patients, including 21.4 months of survival benefit for a woman with an eye-bulging tumour that was 100 per cent resolved after treatment.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
BriaCell Therapeutics Corp. (BCT) is up 1.95 per cent, trading at C$9.43 at 12:24 pm ET.